I dont know what Trek from LSE smoking but i badly need same ;)
He thought to pump before open so that he can sell to others...
Hi R00st3R,
I think todays interims answer your questions. All good at ONC. Well actually very good!
Should be a cracking day today!
Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment.
Wish I could buy more at this price!
Usual caveats
Trek |
H1'23 results out today from Oncimmune. All the details here. |
Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.
All the details here. |
Agreed, many a slip between the cup and the lip, but an easy buy if they are able to deal with the refinancing. |
Link to post results interview |
These numbers are for the 15 months (changed accounting period) to August last year.
Quite a bit has happened since then, not least of which is a big increase in the revenue at immunoinsights business and a smallish CR. As they said in the release today, their income in the 6 months since Aug 22 is higher than for the 15 months reported. They also say they will be operationally cash profitable for the FY ending Aug 23. |
There is no way IPL will pull the plug on a business that is clearly able to repay them, they will ask for a pound of flesh but not pull the plug, after all lending to healthcare startup is their business. |
"Business continues to perform in line with previously reported expectations, and the Group is now expecting to be operating cashflow positive in FY2023." |
Massive cash burn - But DYOR. |
Final results (y/e Aug'22) out today from global immunodiagnostics firm, Oncimmune
All the details here. |
Terrific news today from Oncimmune, who is partnering with with Siemens Healthineers to improve the assessment of indeterminate pulmonary nodules.
All the details here. |
Excellent insights here from Oncimmune CEO Adam Hill - who takes me through the recent surge in new orders, £2.1m top up fund raise and strategic options for the EarlyCDT Lung division.
www.linkedin.com/posts/paul-hill-a5994116_the-futures-bright-the-futures-oncimmune-activity-7011738989124591616-LY6X?utm_source=share&utm_medium=member_desktop |
>>>> |
More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.
All the news and investor commentary here.
www.linkedin.com/posts/paul-hill-a5994116_onc-onc-onc-activity-7010866256543162368-xqRF?utm_source=share&utm_medium=member_desktop |
Leading immunodiagnostics firm Oncimmune successfully competes a £2.1m top up fund raise. All the details & commentary here.
www.linkedin.com/posts/paul-hill-a5994116_onc-onc-onc-activity-7008815276058148864-_w4p?utm_source=share&utm_medium=member_desktop |
Interesting. Not been in these for sometime but nice to see premium, if small. The risk warning though about needing more funds come summer if trading doesn't meet the new aggressive target, is somewhat of a dampener. |
There are 2 golden rules when investing in nascent healthcare stocks.
Find out here what they are & potentially how to profit from these secular tailwinds.
www.linkedin.com/posts/paul-hill-a5994116_vrci-llai-onc-activity-7002167778723950592-M7p9?utm_source=share&utm_medium=member_desktop |
Jul 1, 2019 |
where is the RNS ? |
hxxps://www.fiercebiotech.com/medtech/biodesix-acquires-oncimmune-s-u-s-lab-for-rule-lung-nodule-cancer-blood-test |
looks like a placing coming hear |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
